Kailera Therapeutics (NASDAQ:KLRA) Posts Earnings Results, Misses Estimates By $0.35 EPS

Kailera Therapeutics (NASDAQ:KLRA) posted its quarterly earnings results on Wednesday. The company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.35), FiscalAI reports.

Kailera Therapeutics Trading Up 2.4%

Shares of Kailera Therapeutics stock traded up $0.45 during midday trading on Thursday, reaching $19.04. The company had a trading volume of 65,471 shares, compared to its average volume of 704,216. The stock has a market capitalization of $2.47 billion and a price-to-earnings ratio of -0.01. Kailera Therapeutics has a fifty-two week low of $16.39 and a fifty-two week high of $28.23. The stock’s fifty day moving average is $19.52.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. JPMorgan Chase & Co. began coverage on shares of Kailera Therapeutics in a research note on Tuesday, May 12th. They issued an “overweight” rating and a $30.00 price target on the stock. Wall Street Zen cut shares of Kailera Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Jefferies Financial Group assumed coverage on Kailera Therapeutics in a research note on Tuesday, May 12th. They issued a “buy” rating and a $48.00 price target for the company. Zacks Research upgraded shares of Kailera Therapeutics to a “hold” rating in a research report on Wednesday, May 13th. Finally, William Blair assumed coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They issued an “outperform” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $42.75.

About Kailera Therapeutics

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.